Home › Compare › GRCL vs RYLD

GRCL vs RYLD: Dividend Comparison 2026

GRCL yields 19.51% · RYLD yields 12.39%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRCL wins by $25.6K in total portfolio value
10 years
GRCL
GRCL
● Live price
19.51%
Share price
$10.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$70.9K
Annual income
$6,394.90
Full GRCL calculator →
RYLD
RYLD
● Live price
12.39%
Share price
$14.64
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.3K
Annual income
$2,682.98
Full RYLD calculator →

Portfolio growth — GRCL vs RYLD

📍 GRCL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRCLRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRCL + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GRCL pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRCL
Annual income on $10K today (after 15% tax)
$1,658.54/yr
After 10yr DRIP, annual income (after tax)
$5,435.67/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,053.44/yr
After 10yr DRIP, annual income (after tax)
$2,280.53/yr
At 15% tax rate, GRCL beats the other by $3,155.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRCL + RYLD for your $10,000?

GRCL: 50%RYLD: 50%
100% RYLD50/50100% GRCL
Portfolio after 10yr
$58.1K
Annual income
$4,538.94/yr
Blended yield
7.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GRCL right now

GRCL
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Price Target
$6.00
-41.5% upside vs current
Range: $6.00 — $6.00
Altman Z
1.5
Piotroski
3/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRCL buys
0
RYLD buys
0
No recent congressional trades found for GRCL or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRCLRYLD
Forward yield19.51% ✓12.39%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$70.9K ✓$45.3K
Annual income after 10y$6,394.90 ✓$2,682.98
Total dividends collected$39.8K ✓$19.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: GRCL vs RYLD ($10,000, DRIP)

YearGRCL PortfolioGRCL Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$12,651$1,951.22$11,939$1,239.34+$712.00 → GRCL
2$15,844$2,307.04$14,158$1,382.89+$1.7K → GRCL
3$19,653$2,700.22$16,682$1,532.59+$3.0K → GRCL
4$24,159$3,130.30$19,537$1,687.64+$4.6K → GRCL
5$29,447$3,596.27$22,752$1,847.20+$6.7K → GRCL
6$35,604$4,096.58$26,355$2,010.43+$9.2K → GRCL
7$42,726$4,629.21$30,376$2,176.45+$12.3K → GRCL
8$50,908$5,191.72$34,847$2,344.43+$16.1K → GRCL
9$60,253$5,781.31$39,800$2,513.54+$20.5K → GRCL
10$70,866$6,394.90$45,269$2,682.98+$25.6K → GRCL

GRCL vs RYLD: Complete Analysis 2026

GRCL — Stock

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Full GRCL Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this GRCL vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRCL vs SCHDGRCL vs JEPIGRCL vs OGRCL vs KOGRCL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.